The IHC scoring of the dissected tumour tissues revealed that the percentage of Ki‐67‐ and PCNA‐positive cells was distinctly reduced in the co‐treatment group with PET and sorafenib than those in single‐agent treatment groups (Figure 6A‐C). This evidence concerns the gene MKI67 and neoplasm.